Cargando…
Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy
PD-1/PD-L1 blocking therapy has become one of the most promising methods in the field of tumor treatment. However, it encounters the challenge of immune escape due to the exhaustion of T cells. Studies have shown that the epigenetic regulation drug histone deacetylase inhibitor (HDACi) may be able t...
Autores principales: | Lu, Fengkun, Hou, Lei, Wang, Sizhen, Yu, Yingjie, Zhang, Yunchang, Sun, Linhong, Wang, Chen, Ma, Zhiqiang, Yang, Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158275/ https://www.ncbi.nlm.nih.gov/pubmed/34036867 http://dx.doi.org/10.1080/10717544.2021.1927246 |
Ejemplares similares
-
Low-dose HDACi potentiates anti-tumor activity of macrophages in immunotherapy
por: Li, Xiaolei, et al.
Publicado: (2021) -
A Sequential Therapeutic Hydrogel With Injectability and Antibacterial Activity for Deep Burn Wounds’ Cleaning and Healing
por: Wang, Sizhen, et al.
Publicado: (2021) -
HDACIs and the inhibition of invasive potential
por: Dent, Paul
Publicado: (2013) -
Sodium Butyrate Enhances the Cytotoxic Effect of Etoposide in HDACi-Sensitive and HDACi-Resistant Transformed Cells
por: Gnedina, Olga O., et al.
Publicado: (2023) -
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
por: Suraweera, Amila, et al.
Publicado: (2018)